278 related articles for article (PubMed ID: 32341031)
21. Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression.
Cappelletti V; Verzoni E; Ratta R; Vismara M; Silvestri M; Montone R; Miodini P; Reduzzi C; Claps M; Sepe P; Daidone MG; Procopio G
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098246
[TBL] [Abstract][Full Text] [Related]
22. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
Weiss S; Lamy P; Rusan M; Nørgaard M; Ulhøi BP; Knudsen M; Kassentoft CG; Farajzadeh L; Jensen JB; Pedersen JS; Borre M; Sørensen KD
Int J Cancer; 2024 Jul; 155(2):298-313. PubMed ID: 38602058
[TBL] [Abstract][Full Text] [Related]
23. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
24. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
25. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
[TBL] [Abstract][Full Text] [Related]
26. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
27. High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.
Wu Y; Schoenborn JR; Morrissey C; Xia J; Larson S; Brown LG; Qu X; Lange PH; Nelson PS; Vessella RL; Fang M
J Mol Diagn; 2016 Jan; 18(1):131-43. PubMed ID: 26607774
[TBL] [Abstract][Full Text] [Related]
28. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.
Xia Y; Huang CC; Dittmar R; Du M; Wang Y; Liu H; Shenoy N; Wang L; Kohli M
Oncotarget; 2016 Jun; 7(24):35818-35831. PubMed ID: 27127882
[TBL] [Abstract][Full Text] [Related]
29. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES
Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
31. Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.
Pal SK; He M; Chen L; Yang L; Pillai R; Twardowski P; Hsu J; Kortylewski M; Jones JO
Urol Oncol; 2018 Apr; 36(4):162.e1-162.e6. PubMed ID: 29289429
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
Goodman OB; Fink LM; Symanowski JT; Wong B; Grobaski B; Pomerantz D; Ma Y; Ward DC; Vogelzang NJ
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1904-13. PubMed ID: 19505924
[TBL] [Abstract][Full Text] [Related]
33. Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability.
Tayoun T; Oulhen M; Aberlenc A; Farace F; Pawlikowska P
Cells; 2021 Feb; 10(2):. PubMed ID: 33562741
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents.
Economos C; Morrissey C; Vessella RL
Curr Opin Urol; 2012 May; 22(3):190-6. PubMed ID: 22328019
[TBL] [Abstract][Full Text] [Related]
35. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam PJ; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
Genome Med; 2018 Nov; 10(1):85. PubMed ID: 30458854
[TBL] [Abstract][Full Text] [Related]
36. Liquid biopsy: ready to guide therapy in advanced prostate cancer?
Hegemann M; Stenzl A; Bedke J; Chi KN; Black PC; Todenhöfer T
BJU Int; 2016 Dec; 118(6):855-863. PubMed ID: 27430478
[TBL] [Abstract][Full Text] [Related]
37. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
38. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Vogelzang NJ; Fizazi K; Burke JM; De Wit R; Bellmunt J; Hutson TE; Crane E; Berry WR; Doner K; Hainsworth JD; Wiechno PJ; Liu K; Waldman MF; Gandhi A; Barton D; Jungnelius U; Fandi A; Sternberg CN; Petrylak DP
Eur Urol; 2017 Feb; 71(2):168-171. PubMed ID: 27522164
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
40. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]